Today, Sunday, June 7, 2026, is the 38th annual National Cancer Survivors Day — observed on the first Sunday of June since 1988 to honor the millions of Americans living beyond a cancer diagnosis.

In New York City, that means celebrating a milestone that would have been hard to imagine for oncologists who entered the profession in the 1970s, when a cancer diagnosis was often viewed as a likely death sentence. Today, the city of 8.3 million people is home to an estimated 500,000 living cancer survivors, people who have completed treatment and are living with, through, or beyond their diagnosis.

That number reflects more than personal resilience. It is also the result of decades of progress in cancer research, earlier detection, more effective treatments, and better long-term care for survivors. Together, these advances have helped transform many cancers from fatal diseases into conditions that can often be treated, managed, or cured.

The national data supporting this transformation is documented in the American Cancer Society's Cancer Statistics 2026 report: the five-year relative survival rate for all cancers combined has reached a historic milestone of 70% — up from 49% in the mid-1970s.

Since the cancer death rate reached its peak in 1991, it has fallen by 34%, preventing an estimated 4.8 million deaths. For New York City residents, those numbers are more than statistics.

They are reflected in the woman in Flushing who completed breast cancer treatment and is now five years in remission. They are reflected in the man in the Bronx whose prostate cancer was detected at Stage 1 during a routine PSA screening. They are reflected in the teenager from Staten Island whose leukemia responded to CAR T-cell therapy.

Each is a survivor. Each is living proof of medical advances that were unavailable to previous generations. National Cancer Survivors Day shines a light on those successes, reminding both the public and the medical community that progress against cancer is real and that it continues to save lives.

Read more

The Breakthroughs Driving 2026 Survivorship

This year's National Cancer Survivors Day comes at a time of remarkable progress in cancer research. Just one week ago, researchers gathered at the 2026 ASCO Annual Meeting in Chicago and unveiled two findings that could change cancer care in the years ahead.

The first involved daraxonrasib, a new targeted treatment tested in a Phase 3 clinical trial. Researchers found that the drug nearly doubled survival for patients with metastatic pancreatic cancer, increasing median survival from 6.7 months to 13.2 months while reducing the risk of death by 60%. Pancreatic cancer remains one of the deadliest forms of the disease, claiming nearly 53,000 American lives each year. For a cancer that has seen few major breakthroughs in recent decades, the results mark a significant step forward.

The second finding came from a Penn Medicine study involving 111,646 women. Researchers reported that GLP-1 drugs reduce breast cancer incidence by 30%, suggesting that medications already widely used to treat obesity and diabetes may also help lower the risk of one of the most common cancers among women.

Read more

Personalized mRNA Cancer Vaccines: The Technology Being Tested in New York Right Now

For cancer survivors and patients in New York City, another major finding from ASCO 2026 is offering new hope.

Researchers reported results from a mid-stage clinical trial showing that a personalized cancer vaccine, used together with the immunotherapy drug Keytruda, helped prevent melanoma from returning after surgery in patients with advanced disease. The vaccine, developed by Moderna and Merck, uses the same mRNA technology that powered many COVID-19 vaccines. What makes it different is that each dose is custom-made for an individual patient. Scientists analyze a patient's tumor and create a vaccine designed to help the immune system recognize and attack cancer cells if they come back.

The study focused on patients with stage 3 and stage 4 melanoma who had already undergone surgery to remove their tumors. Researchers found that the vaccine-and-immunotherapy combination showed strong potential in reducing the risk of cancer recurrence.

Several leading New York City medical centers are helping test personalized mRNA cancer vaccines in ongoing clinical trials. These include Memorial Sloan Kettering Cancer Center, NYU Langone Health's Perlmutter Cancer Center, and Columbia University Irving Medical Center.

For survivors who worry about their cancer returning, and for newly diagnosed patients who may qualify, experts say it may be worth speaking with an oncologist about available clinical trials and whether these new treatments could be an option. The NCI's Cancer Trials Support Unit trial locator lists all open enrollment studies in New York by diagnosis type.

What Survivorship Science Has Learned That Medicine Is Still Applying

National Cancer Survivors Day is not only a celebration — it is also a reminder of what the survivorship science has revealed about the needs that are not being met.

A 2026 American Cancer Society report on survivorship found that many cancer survivors face long-term health challenges, including heart damage linked to chemotherapy and radiation, secondary cancers, hormone-related disorders, emotional distress, and memory and concentration problems often called "chemo brain." The report noted that these issues often require specialized follow-up care, yet they may fall outside the focus of standard cancer treatment and can be difficult for primary care physicians to identify and manage.

New York City's density of academic medical systems provides survivorship programs that most cities lack. Memorial Sloan Kettering's Life After Cancer Care program, NYU Langone's survivorship clinic, and Montefiore's integrated survivorship services are among the most comprehensive in the country. For survivors in New York: today is the right day to schedule a survivorship care visit if you have not had one in the past year.